NASDAQ: MRUSMerus Nv Stock
$40.82+0.37 (+0.91%)
Updated Apr 23, 2024
MRUS Price
$40.82
Fair Value Price
-$14.14
Market Cap
$2.36B
52 Week Low
$18.21
52 Week High
$52.04
P/E
-13.61x
P/B
6.63x
P/S
32.29x
PEG
N/A
Dividend Yield
N/A
Revenue
$43.95M
Earnings
-$154.94M
Gross Margin
100%
Operating Margin
-378.31%
Profit Margin
-352.6%
Debt to Equity
0.28
Operating Cash Flow
-$142M
Beta
1.07
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MRUS Overview
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MRUS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MRUS ($40.82) is overvalued by 388.64% relative to our estimate of its Fair Value price of -$14.14 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MRUS ($40.82) is not significantly undervalued (388.64%) relative to our estimate of its Fair Value price of -$14.14 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MRUS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MRUS due diligence checks available for Premium users.
Be the first to know about important MRUS news, forecast changes, insider trades & much more!
MRUS News
Valuation
MRUS fair value
Fair Value of MRUS stock based on Discounted Cash Flow (DCF)
Price
$40.82
Fair Value
-$14.14
Undervalued by
388.64%
MRUS ($40.82) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MRUS ($40.82) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MRUS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MRUS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-13.61x
Industry
16.46x
Market
41.92x
MRUS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.63x
Industry
5.93x
MRUS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MRUS's financial health
Profit margin
Revenue
$8.9M
Net Income
-$60.2M
Profit Margin
-672.9%
MRUS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MRUS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$455.5M
Liabilities
$99.2M
Debt to equity
0.28
MRUS's short-term assets ($368.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MRUS's short-term assets ($368.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MRUS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MRUS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$36.3M
Investing
-$2.1M
Financing
$1.5M
MRUS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MRUS vs Biotech Stocks
Merus Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.